CAR T-cell Therapy | Specialty

Dr. Sotomayor on the Durability of CAR T Cells in Hematologic Malignancies

October 4th 2019

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses the durability of CAR T cells, as well as ways to combat immune escape mechanisms in hematologic malignancies.

Dr. Avigan on CAR T-Cell Therapy in Lymphoproliferative Disease

September 28th 2019

David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.

Dr. Frey on CAR T-Cell Therapy in High-Risk ALL

September 27th 2019

Noelle Frey, MD, MSCE, discusses the use of CAR T-cell therapy in acute lymphocytic leukemia.

Dr. Marasco on Engineering CAR T Cells

September 25th 2019

Wayne A. Marasco, MD, PhD, discusses ways CAR T cells are being engineered to avoid on-target adverse events in solid tumors.

CAR T Cells Could Revolutionize RCC Treatment

September 23rd 2019

Wayne A. Marasco, MD, PhD, discusses the intricacy of engineering CAR T cells and the early data he has observed with CAR T-cell therapy in renal cell carcinoma.

Dr. Shah on the Use of Tisagenlecleucel in Pediatric ALL

September 21st 2019

Bijal D. Shah, MD, associate professor, Department of Malignant Hematology, Moffitt Cancer Center, discusses the use of CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia (ALL).

Dr. Sotomayor on Differences Between FDA-Approved CAR T-Cell Therapies

September 21st 2019

Eduardo Sotomayor, MD, professor of medicine, Department of Hematology and Oncology, and director, GW Cancer Center, discusses differences between FDA-approved CAR T-cell therapies.

Sasine Highlights Strides With CAR T-Cell Therapy in Hematologic Cancers

September 16th 2019

Joshua P. Sasine, MD, PhD, spotlights some of the strategies under investigation to improve the safety and efficacy of CAR T-cell therapy in hematologic malignancies.

Tisagenlecleucel Maintains Efficacy in Real-World Setting

September 15th 2019

Early results from a prospective postmarketing assessment showed that tisagenlecleucel induced responses similar to those seen in pivotal trials for children and adolescents with B-cell acute lymphoblastic leukemia and adults with diffuse large B-cell lymphoma.

Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

September 14th 2019

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Dr. Maloney on the Registry for Real World Data of CAR T-Cell Therapy in ALL

September 13th 2019

David G. Maloney, MD, PhD, discusses the initiative to use the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry to report real world experience of tisagenlecleucel CAR T cells targeting CD19 in patients with acute lymphoblastic leukemia.

Dr. Sasine on New Developments With CAR T-Cell Therapy

September 13th 2019

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, hematologist, and oncologist, University of California, Los Angeles, discusses new developments with CAR T-cell therapy.

Emerging CAR T-Cell Therapies in Hematologic Cancers

September 6th 2019

Xiuli Wang, PhD, discusses emerging CAR T-cell therapy in hematologic cancers.

Dr. Sasine on Determining Outlook With CAR T-Cell Therapy in Hematologic Cancers

August 27th 2019

Joshua P. Sasine, MD, PhD, clinical instructor of medicine, University of California, Los Angeles, discusses how to determine if a patient will have a response to CAR T-cell therapy.

Identifying Patients and Treating With CAR T-Cell Therapy

August 13th 2019

Stem Cell Transplantation and Novel Therapy

August 13th 2019

Optimizing Therapy for Patients With Multiple Myeloma

August 13th 2019

Navigating Through Testicular Cancer Treatment

August 13th 2019

Lisocabtagene Maraleucel Elicits Undetectable MRD in Relapsed/Refractory CLL

August 6th 2019

Tanya Siddiqi, MD, explains how novel agents are improving the treatment landscape for chronic lymphocytic leukemia, citing examples from the TRANSCEND CLL 004 trial.

Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin Lymphoma

August 5th 2019

Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.